PNTG (The Pennant Group, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by PNTG officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-10 | Kirk Sterling Cheney | EVP, GC and Corp Secy | Sell | — | — |
| 2026-08-10 | Brent Guerisoli | Chief Executive Officer | Sell | — | — |
| 2026-08-10 | Jason Paul Steik | Chief Clinical Officer | Sell | — | — |
| 2026-07-17 | Suzanne D. Snapper | Director | A | — | — |
| 2026-07-17 | STEPHEN M R COVEY | Director | A | — | — |
| 2026-07-17 | BARRY M SMITH | Director | A | — | — |
| 2026-07-17 | Scott E Lamb | Director | A | — | — |
| 2026-07-17 | Gregory K Morris Sr. | Director | A | — | — |
| 2026-07-17 | John G. Nackel | Director | A | — | — |
| 2026-07-17 | Christopher R. Christensen | Director | A | — | — |
| 2026-07-14 | Brent Guerisoli | Chief Executive Officer | MIXED | — | — |
| 2026-07-09 | Brent Guerisoli | Chief Executive Officer | MIXED | — | — |
| 2026-05-27 | Brent Guerisoli | Chief Executive Officer | MIXED | — | — |
| 2026-04-17 | Suzanne D. Snapper | Director | A | — | — |
| 2026-04-17 | BARRY M SMITH | Director | A | — | — |
| 2026-04-17 | John J Gochnour | Chief Operating Officer | A | — | — |
| 2026-04-17 | Scott E Lamb | Director | A | — | — |
| 2026-04-17 | Brent Guerisoli | Chief Executive Officer | A | — | — |
| 2026-04-17 | STEPHEN M R COVEY | Director | A | — | — |
| 2026-04-17 | John G. Nackel | Director | A | — | — |
| 2026-04-17 | Kirk Sterling Cheney | EVP, GC and Corp Secy | A | — | — |
| 2026-04-17 | Gregory K Morris Sr. | Director | A | — | — |
| 2026-04-17 | Lynette Walbom | Chief Financial Officer | A | — | — |
| 2026-04-17 | Christopher R. Christensen | Director | A | — | — |
| 2026-03-12 | Kirk Sterling Cheney | EVP, GC and Corp Secy | A | — | — |
| 2026-03-12 | Jason Paul Steik | Chief Clinical Officer | A | — | — |
| 2026-03-12 | Lynette Walbom | Chief Financial Officer | A | — | — |
| 2026-03-12 | Brent Guerisoli | Chief Executive Officer | A | — | — |
| 2026-03-12 | John J Gochnour | Chief Operating Officer | A | — | — |
| 2026-01-21 | Scott E Lamb | Director | A | — | — |
| 2026-01-21 | Suzanne D. Snapper | Director | A | — | — |
| 2026-01-21 | Gregory K Morris Sr. | Director | A | — | — |
| 2026-01-21 | STEPHEN M R COVEY | Director | A | — | — |
| 2026-01-21 | John G. Nackel | Director | A | — | — |
| 2026-01-21 | Christopher R. Christensen | Director | A | — | — |
| 2026-01-21 | BARRY M SMITH | Director | A | — | — |
| 2025-11-13 | Kirk Sterling Cheney | EVP, GC and Corp Secy | M | — | — |
| 2025-10-16 | Scott E Lamb | Director | A | — | — |
| 2025-10-16 | John G. Nackel | Director | A | — | — |
| 2025-10-16 | Christopher R. Christensen | Director | A | — | — |
| 2025-10-16 | Gregory K Morris Sr. | Director | A | — | — |
| 2025-10-16 | BARRY M SMITH | Director | A | — | — |
| 2025-10-16 | STEPHEN M R COVEY | Director | A | — | — |
| 2025-10-16 | Suzanne D. Snapper | Director | A | — | — |
| 2025-10-14 | BARRY M SMITH | Director | M | — | — |
| 2025-08-07 | Kirk Sterling Cheney | EVP, GC and Corp Secy | Sell | — | — |
| 2025-07-31 | Brent Guerisoli | Chief Executive Officer | Sell | — | — |
| 2025-07-17 | Christopher R. Christensen | Director | A | — | — |
| 2025-07-17 | STEPHEN M R COVEY | Director | A | — | — |
| 2025-07-17 | BARRY M SMITH | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 1,368,108 | — |
| — | Director | 769,338 | — |
| — | Director | 230,364 | — |
| — | Director | 177,265 | — |
| — | Chief Operating Officer | 145,464 | — |
| — | Director | 102,499 | — |
| — | Chief Executive Officer | 99,544 | — |
| — | Chief Investment Officer | 67,634 | — |
| — | Director | 58,935 | — |
| — | Director | 44,050 | — |
| — | Director | 37,300 | — |
| — | Chief Financial Officer | 34,807 | — |
| — | Director | 30,275 | — |
| — | EVP, GC and Corp Secy | 18,401 | — |
| — | Chief Clinical Officer | 15,106 | — |
| — | Chief Financial Officer | 10,688 | — |
| — | Director | 6,750 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PNTG quote page; the site-wide leaderboard is on the insider transactions hub.